Didanosine contraindications: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Didanosine}} {{CMG}}; {{AE}} {{AZ}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect" |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Didanosine}} | {{Didanosine}} | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}}==CONTRAINDICATIONS== | ||
These recommendations are based on either drug interaction studies or observed clinical toxicities. | |||
===Allopurinol=== | |||
Coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity. | |||
===Ribavirin=== | |||
Coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. | |||
==References== | ==References== | ||
Revision as of 19:17, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]==CONTRAINDICATIONS==
These recommendations are based on either drug interaction studies or observed clinical toxicities.
Allopurinol
Coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity.
Ribavirin
Coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin.
References
Adapted from the FDA Package Insert.